Medical research Books
Taylor & Francis Ltd Interface between Regulation and Statistics in Drug Development
a huge range and FREE tracked UK delivery on ALL orders.
£43.69
Taylor & Francis Ltd Simultaneous Global New Drug Development
a huge range and FREE tracked UK delivery on ALL orders.
£68.39
Taylor & Francis Ltd Bronchoalveolar Lavage in Basic Research and Clinical Medicine
a huge range and FREE tracked UK delivery on ALL orders.
£59.99
Taylor & Francis Ltd Bronchoalveolar Lavage in Basic Research and Clinical Medicine
a huge range and FREE tracked UK delivery on ALL orders.
£99.99
Taylor & Francis Ltd Analyzing Health Data in R for SAS Users
a huge range and FREE tracked UK delivery on ALL orders.
£45.99
Taylor & Francis Breast Cancer Gene Research and Medical Practices
a huge range and FREE tracked UK delivery on ALL orders.
£39.99
Taylor & Francis Ltd PatientSpecific Stem Cells
a huge range and FREE tracked UK delivery on ALL orders.
£58.99
Taylor & Francis Ltd Local Cells Global Science
a huge range and FREE tracked UK delivery on ALL orders.
£37.99
Taylor & Francis Ltd Researching Reflecting and Writing about Work
a huge range and FREE tracked UK delivery on ALL orders.
£109.25
Taylor & Francis Researching Reflecting and Writing about Work
Book SynopsisResearching, Reflecting and Writing about Work provides a guide to the research skills and critical thinking required to complete a research project for professional learning courses in counselling and psychotherapy. Written at a level easily accessible to those enrolled on a work-based qualification as well as those considering postgraduate research at master''s level, this book includes: how we reflect on our work discussion on preparation and structuring of a case study how to present work in supervision with advice on process recording essay plan structures and appropriate methodologies for research ethical considerations and critical linking dilemmas and tensions involved in research at work'. Key learning points and reflective exercises are included throughout and theory is supported by contributions detailing specific learning experiences from a variety of work setTrade Review"This is an important book. For the first time the gamut of diverse training programmes for therapists are linked in a systematic and productive way with the research methodologies currently in use." - Rom Harré, from the Preface"By providing examples of the experience of counsellors in pursuing research projects that have meaning and value for their clients and themselves, the contributors to the book are able to show that research can indeed represent a significant means of extending and deepening insight and understanding in ways that are relevant to understanding the purpose and process of therapy, and which enhance rather than undermine the therapeutic relationship." - John McLeod, from the Foreword"Researching, Reflecting and Writing about Work can be dipped into, and chapters hold their own, independtly of the whole. However, the book's true richness comes through best from reading it in full... I highly recommend it, and expect to refer to it often with a range of students." - Sandra Taylor, Healthcare, Counselling and Psychotherapy Journal, July 2010"This is an important book. For the first time the gamut of diverse training programmes for therapists are linked in a systematic and productive way with the research methodologies currently in use." - Rom Harré, from the Preface. "By providing examples of the experience of counsellors in pursuing research projects that have meaning and value for their clients and themselves, the contributors to the book are able to show that research can indeed represent a significant means of extending and deepening insight and understanding in ways that are relevant to understanding the purpose and process of therapy, and which enhance rather than undermine the therapeutic relationship." - John McLeod, from the Foreword. Table of ContentsHarré, Preface. Gardner, Introduction. Gardner, Coombs, Learning and Researching as an Adult Professional. Gardner, Coombs, Ethical Dilemmas in Training and in Research. Gardner, Coombs, Using the Case Study Approach for Training and Research. Gardner, Coombs, Choosing a Research Paradigm. Whitehead, Research Using Focus Groups in an Organisational Setting. Barnet, Research in the Voluntary Sector. Larcombe, Research in the Public Sector. Cole, Research in the Community with a Feminist Approach. Larcombe, Gardner, Coombs, Going Public – Getting Your Work Out to a Wider Audience. Coombs, The Way Forward.
£34.19
Taylor & Francis Ltd Involving Children and Young People in Health and Social Care Research
a huge range and FREE tracked UK delivery on ALL orders.
£42.99
Taylor & Francis Ltd Local Cells Global Science
a huge range and FREE tracked UK delivery on ALL orders.
£14.99
Taylor & Francis Ltd Making Research Matter
a huge range and FREE tracked UK delivery on ALL orders.
£114.00
Taylor & Francis Ltd Making Research Matter
a huge range and FREE tracked UK delivery on ALL orders.
£31.99
Taylor & Francis Ltd Involving Children and Young People in Health and Social Care Research
a huge range and FREE tracked UK delivery on ALL orders.
£142.50
Taylor & Francis New Developments in Dementia Prevention Research
a huge range and FREE tracked UK delivery on ALL orders.
£123.50
Taylor & Francis Ltd Bayesian Analysis with R for Drug Development
Book SynopsisDrug development is an iterative process. The recent publications of regulatory guidelines further entail a lifecycle approach. Blending data from disparate sources, the Bayesian approach provides a flexible framework for drug development. Despite its advantages, the uptake of Bayesian methodologies is lagging behind in the field of pharmaceutical development.Written specifically for pharmaceutical practitioners, Bayesian Analysis with R for Drug Development: Concepts, Algorithms, and Case Studies, describes a wide range of Bayesian applications to problems throughout pre-clinical, clinical, and Chemistry, Manufacturing, and Control (CMC) development. Authored by two seasoned statisticians in the pharmaceutical industry, the book provides detailed Bayesian solutions to a broad array of pharmaceutical problems.Features Provides a single source of information on Bayesian statistics for drug development CoTable of ContentsBackground. Drug Research and Development. Basics of Bayesian analysis. Bayesian Estimation of Sample Size and Power. Pre-Clinical and Clinical Research. Pre-clinical efficacy study. Futility analysis. Phase 3 Clinical Trial. Chemistry, Manufacturing, and Control. Analytical method. Process Development. Bayesian Approach to Statistical Process Control.
£39.99
Taylor & Francis Ltd Challenging Cases in Clinical Research Ethics
Book SynopsisClinical research ethics consultation has emerged in the last 15 years as a service to those involved in the conduct of clinical research who face challenging issues for which more than one course of action may be justified. To respond to a growing field and need for opportunities to share knowledge and experience, the Clinical Research Ethics Consultation Collaborative, established in 2014, holds monthly webinars for its 90 members to present their most challenging cases to each other and engage in substantive discussion. Every year, the group selects the four most interesting cases with accompanying commentaries for publication in the American Journal of Bioethics. This timely book brings together these cases and commentaries under a range of common themes for the first time, creating a permanent collection in book format that encourages and supports readers to gain a better understanding of the ethical challenges that they may face, and providing them with a conveniTable of ContentsForewordIntroduction A Framework for Research Ethics. Principles of Research Ethics. Topics in Research Ethics . Values of Research Ethics. Section 1. Collaborative PartnershipIntroductionCase 1.1 Supporting Community-Academic Research Partnerships: Reflections from the GroundCommentary 1.1.1: Community Partnered Participatory Research in Southeast Louisiana Communities Threatened by Climate Change: The C-LEARN EXPERIENCE. Commentary 1.1.2: Leveraging Academic Institutional Structures to Support Asian American Community Organizations’ Engagement in Research: The Korean Community Service Center. Commentary 1.1.3: Engaging the Sickle Cell Community in Participatory Research. Commentary 1.1.4: Being in Good Community: Engagement in Support of Indigenous Sovereignty.Case 1.2 Protecting Research Subject Welfare in Preventative Trials for Autosomal Dominant Alzheimer's DiseaseCommentary 1.2.1: When There Are Only Two Who Can Tango: Ethical Concerns at the Juncture of Highly Novel Interventions and Precisely Targeted Research Populations. Commentary 1.2.2: Conceptualization and Assessment of Vulnerability in a Complex International Alzheimer’s Research Study. Commentary 1.2.3: Barriers and Facilitators to the Consent Process in a Study of Complex Genetic Factors.Case 1.3 Studying the Role of Financial Incentives to Promote Hepatitis B Vaccination in a Community ClinicCommentary 1.3.1: Treatment Incentives and the Nature of the Doctor-Patient Relationship. Commentary 1.3.2: The Ethics of Studying Financial Incentives in Public Health Implementation: Study Design Challenges. Commentary 1.3.3: You Can Lead a Horse to Water, But Can You Pay to Make Him Drink? An Ethical Analysis of Research on Using Incentives to Promote Patient Health.Case 1.4 A Cluster Randomized Trial to Screen for Abusive Head Trauma in the Paediatric Intensive Care Unit--How to Manage Site-Specific Evidence of Racial/Ethnic DisparityCommentary 1.4.1: Issues of Justice and Risk: Setting Stopping Criteria in Cluster-Randomized Trials. Commentary 1.4.2: Clinical Trials Not Causing Harm with Potential for Realizing Benefit Should Continue. Commentary 1.4.3: Responding to Implicit Bias in Abusive Head Trauma Evaluations and Reporting in the PICU: Ethical Consideration During a Clinical Trial.Case 1.5 When a Clinical Trial Is the Only OptionCommentary 1.5.1: "Respect for Persons," Not "Respect for Citizens". Commentary 1.5.2: The Potentially High Cost of a Free Clinical Trial. Commentary 1.5.3: Contextualizing "Choice" for Undocumented Immigrants in U.S. Clinical Trials Research.Case 1.6 A Randomized Trial of Rapamycin to Increase Longevity and Healthspan in Companion Animals: Navigating the Boundary Between Protections for Animal Research and Human Subjects ResearchCommentary 1.6.1: Rapamycin: Risking Harm for Canine Longevity. Commentary 1.6.2: Companion Animal Studies: Slipping Through a Research Oversight Gap. Commentary 1.6.3: Research to Promote Longevity and Health Span in Companion Dogs: A Paediatric Perspective.Section 2. Respect for ParticipantsIntroduction.Case 2.1 Ethical Considerations for Unblinding a Participant’s Assignment to Interpret a Resolved Adverse EventCommentary 2.1.1: Considerations for Unblinding in Biopharmaceutical IndustrySponsored Trials. Commentary 2.1.2: Blinds and Research Risks. Commentary 2.1.3: The Scientific and Social Implications of Unblinding a Study Subject.Case 2.2 Should Research Participants Be Notified About Results of Currently Unknown by Potential Significance?Commentary 2.2.1: The Need for National Guidance Around Informed Consent About GBCA Safety. Commentary 2.2.2: Returning Individual Research Results Regarding Gadolinium Deposition in the Brain Is the Preferable Choice. Commentary 2.2.3: Research Participants Should Have the Option to Be Notified of Results of Unknown but Potential Significance.Case 2.3 The Ethics of Contacting Family Members of a Subject in a Genetic Research Study to Return Results for an Autosomal Dominant SyndromeCommentary 2.3.1: What Does the Duty to Warn Require? Commentary 2.3.2: Should Researchers Disclose Results to Descendants? Commentary 2.3.3: Relationships Matter: Ethical Considerations for Returning Results to Family Members of Deceased Subjects.Case 2.4 Ethics of Continuing to Provide a Drug on an Open-Label Extension Study for an "Unapproved Indication"Commentary 2.4.1: When Should Open-Label Extension Studies Be Stopped? Commentary 2.4.2: The Role of Clinical Equipoise and Practical Considerations in Deciding Whether to Continue to Provide a Drug on an Open-Label Extension Study for an "Unapproved Indication". Commentary 2.4.3: Open-Label Extension Studies: Are They Really Research?Case 2.5 Supporting Investigators in Challenging Cases: Unease in the Face of an Ethically Appropriate ActionCommentary 2.5.1: Researchers Experience Moral Distress Too! Commentary 2.5.2: Relieving Investigator Angst After an Appropriate but Concerning Ethics Consultation. Commentary 2.5.3: Acknowledging Angst: Research Ethics Consultation in Disclosing Experimental Research Results of Uncertain Benefit.Case 2.6 Recontact and Recruitment of Young Adults Previously Enrolled in Neonatal Herpes Simplex Virus ResearchCommentary 2.6.1: Research Recruitment of Adult Survivors of Neonatal Infections: Is There a Role for Parental Consent? Commentary 2.6.2: A Knotty Problem of Intertwined Rights. Commentary 2.6.3: Consent Is the Cornerstone of Ethically Valid Research: Ethical Issues in Recontacting Subjects Who Enrolled in Research as a Minor.Case 2.7 Genotype-Driven Recruitment in Population-Based Biomedical ResearchCommentary 2.7.1: Genotype-Driven Recruitment Without Deception. Commentary 2.7.2: Harms of Deception in FMR1 Premutation Genotype-Driven Recruitment. Commentary 2.7.3: Genotype-Driven Recruitment and the Disclosure of Individual Research Results.Section 3. Fair Participant SelectionIntroduction.Case 3.1 Is It Ethical to Enrol Cognitively Impaired Adults in Research that is More than Minimal Risk with No Prospect of Benefit?Commentary 3.1.1: Inconsistent Approaches to Research Involving Cognitively Impaired Adults: Why the Broad View of Substituted Judgment Is Our Best Guide. Commentary 3.1.2: Ethical and Regulatory Considerations Regarding Enrolment of Incompetent Adults in More Than Minimal Risk Research as Compared with Children. Commentary 3.1.3: Acceptable Approaches to Enrolling Adults Who Cannot Consent in More Than Minimal Risk Research.Case 3.2 Should Patients Be Required to Undergo Standard Chemotherapy Before Being Eligible for Novel Phase I Immunotherapy Clinical Trials?Commentary 3.2.1: A Rationale for Relaxing the Requirement to Undergo a Noncurative Chemotherapy for Advanced Cancer in a Phase I Immunotherapy Trial. Commentary 3.2.2: Participation of Citizen Scientists in Clinical Research and Access to Research Ethics Consultation. Commentary 3.2.3: Forgoing Conventional Therapy in Phase I Oncology Research: Don’t Forget About the Children.Case 3.3 Involving Pregnant Women in Research: What Should We Recommend When the Regulations Seem Ethically Problematic?Commentary 3.3.1: Conflicts Between Regulations and Ethical Principles: Resolving Ambiguity in Favour of the Ethically Preferable Outcome. Commentary 3.3.2: When to Avoid Giving Advice on the Ethical Conduct of Research. Commentary 3.3.3: When Research Regulations and Ethics Conflict.Case 3.4 Regulatory, Legal, Ethical, and Practical Challenges of Enrolling Wards of the State in ResearchCommentary 3.4.1: Fuzzy Logic: How the Practicalities of State Involvement Shape the Most Ethically Supportable Way Forward. Commentary 3.4.2: Enrolling Foster Youth in Clinical Trials: Avoiding the Harm of Exclusion. Commentary 3.4.3: No Justification to Exclude State Ward from Paediatric Transplant Research. Commentary 3.4.4: Life-Saving Experimental Treatment for a Teenage Ward of the State.Case 3.5 Selecting Children for an Autism Spectrum Disorder Study: Justice and GeographyCommentary 3.5.1: Fair Participant Selection: A Negative Obligation Not to Exclude. Commentary 3.5.2: Unequal Individual Risk and Potential Benefit Balanced by Benefits to the Population at Large in Autism Clinical Trials? Commentary 3.5.3: Justice in Selecting Participants for a Study in Phelan-McDermid Syndrome.Section 4. Favourable Risk-Benefit RatioIntroduction.Case 4.1 Obligations to Act on Patient Reported Outcomes in Electronic Health RecordsCommentary 4.1.1: Informed Consent for PROs in EHR Research: Are Additional Requirements Necessary? Commentary 4.1.2: Patient Reported Outcomes at the Crossroads of Clinical Research and Informatics. Commentary 4.1.3: PROs in the Balance: Ethical Implications of Collecting Patient Reported Outcome Measures in the Electronic Health Record.Case 4.2 A Trial to Test a Novel Approach to Diabetes PreventionCommentary 4.2.1: Is It Ethically Acceptable to Screen Patients for Obstructive Sleep Apnea and Not Offer Them Positive Air Pressure Therapy in a Clinical Trial? Commentary 4.2.2: Can We Breathe Easy If PAP Therapy Is Withheld? Commentary 4.2.3: Risks of Clinical Research Must Be Reasonable and Necessary.Case 4.3 Is It Ethically Appropriate to Refuse to Compensate Participants Who Are Believed to Have Intentionally Concealed Medical Conditions?Commentary 4.3.1: Mutual Obligations in Research and Withholding Payment from Deceptive Participants. Commentary 4.3.2: Best to Exclude but Pay. Commentary 4.3.3: To Pay or Not to Pay? Withholding Payment from Research Participants.Case 4.4 Ethical Drug Development for Rare Childhood Diseases: When There are Limited but Promising Data in Adults, How to Choose Between Safety or Efficacy Studies?Commentary 4.4.1: The Use of Paediatric Extrapolation to Avoid Unnecessary Paediatric Clinical Trials. Commentary 4.4.2: Flexibility Required: Balancing the Interests of Children and Risk in Drug Development for Rare Paediatric Conditions. Commentary 4.4.3: When Higher Risk Does Not Equal Greater Harm: Doing the Most Good in a Limited Paediatric Study Population.Case 4.5 Greater than Minimal Risk, No Direct Benefit – Bridging Drug Trials and Novel Therapy in Paediatric PopulationsCommentary 4.5.1: Balancing Risk and Reward: Greater Research Oversight Is Appropriate for Novel Therapies for Children with Life-Limiting Illness. Commentary 4.5.2: Bringing Known Drugs to Paediatric Research: Safety, Efficacy, and the Ambiguous Minor Increase in Minimal Risk. Commentary 4.5.3: Balancing Scientific Progress with Paediatric Protections: No Direct Benefit Now, But Potential Novel Therapy in the Future. Section 5. Informed ConsentIntroduction.Case 5.1 The Ethics of Disclosing to Research Subjects the Availability of Off-Label Marketed DrugsCommentary 5.1.1: Researchers Have an Ethical Obligation to Disclose the Availability of Off-Label Marketed Drugs. Commentary 5.1.2: The Relevance of Research Study Phase to Disclosure of Off-Label Drug Availability. Commentary 5.1.3: Which Alternatives Should Investigators Disclose to Research Subjects?Case 5.2 A Pragmatic Trial of Suicide Risk Assessment and Ambulance Transport Decision Making Among Emergency Medical Services Providers: Implications for Patient ConsentCommentary 5.2.1: Improving Care for Suicidal Patients While Protecting Human Subjects: Addressing Ethical Challenges in Mental Health Research Involving Emergency Medical Services Providers. Commentary 5.2.2: A Stepwise Approach to Ethically Assess Pragmatic Cluster Randomized Trials: Implications for Informed Consent for Suicide Prevention Implementation Research. Commentary 5.2.3: Informed Consent in a Pragmatic Emergency Suicide Trial: Rejecting the Research-Practice Distinction. Commentary 5.2.4: A Pragmatic Trial for Emergency Medical Service Providers’ Prehospital Response to Suicidality: Consent Is Not Essential, but Limited Patient Engagement May Be Meaningful.Case 5.3 The Obligations to Report Statutory Sexual Abuse Disclosed in a Research StudyCommentary 5.3.1: The Moral and Legal Need to Disclose Despite a Certificate of Confidentiality. Commentary 5.3.2: Informed Consent and the Implications for Statutory Rape Reporting in Research with Adolescents. Commentary 5.3.3: Community, Context, and the Contrasting Roles of Clinicians and Researchers: Challenges Raised by Statutory Rape.Case 5.4 Conjoined Consent: Informed Consent When Donor and Recipient Are Both Research ParticipantsCommentary 5.4.1: Moving Beyond Standard Informed Consent for Interventional Organ Transplant Research. Commentary 5.4.2: Risks to Relationships in Kidney Transplant Research with Living Donors and Recipients.Case 5.5 Navigating Parental Permission for Neonatal ResearchCommentary 5.5.1: Informed Consent and Parental Permission for Research: Rules, Roles, and Relationships. Commentary 5.5.2: Research Involving Premature Infants: Timing Is Everything. Commentary 5.5.3: Precluding Consent by Clinicians Who Are Both the Attending and the Investigator: An Outdated Shibboleth?Case 5.6 Click Here to Complete This Survey: Online Research, Adolescents, and Parental ConsentCommentary 5.6.1: Digital Negotiations: Navigating Parental Permission and Adolescent Assent for On-Line Survey Participation. Commentary 5.6.2: Constrained Adolescent Autonomy for Healthcare Should Include Participation in Survey Research. Commentary 5.6.3: Respecting Parental Permission and Maintaining Flexibility in Online Research Involving Adolescent Participants.Case 5.7 When Professional Meets Personal: How Should Research Staff Advertise on social media for Research Opportunities?Commentary 5.7.1: Sharing Research Opportunities on Personal Social Media Accounts and Fair Subject Selection. Commentary 5.7.2: How Should Investigators Advertise on social media for Research Opportunities?Case 5.8 The Limitation of "Boilerplate" Language in Informed Consent: Single IRB Review of Multisite Genetic Research in Military PersonnelCommentary 5.8.1: The Bane of "Boilerplate" Language in Research Consent Forms: Ensuring Consent Forms Promote Autonomous Authorization. Commentary 5.8.2: Single IRBs Are Responsible to Ensure Consent Language Effectively Conveys the Local Context. Commentary 5.8.3: Solving the Single IRB/Boilerplate Bind: Establishing Institutional Guidelines.Appendix A. Cases Organized by Principles. Appendix B. Cases Organized by Topics. Appendix C. Cases Organized by Values.
£38.99
CRC Press Predicting Solubility of New Drugs
Book SynopsisIn pharmaceutical research, solubility plays a key part in the assessment of pharmacokinetic risks. Poor drug absorption, reduced efficacy, excessive metabolism, and adverse reactions are frequently related to issues of drug solubility. During early discovery research at pharmaceutical companies, many thousands of molecules are considered. Most are rejected due to perceived unfavorable properties. Here the author uses the Wiki-pS0TM database, which forms the backbone of this unique handbook. Also discussed is the emerging class of therapeutically promising research molecules called PROTACs (proteolysis-targeting chimeras), showing a propensity for undruggable' targets.FEATURES A comprehensive and unique listing of measured aqueous intrinsic solubility focusing on drug-like and drug-relevant molecules. The database can be used to predict the solubility of research pharmaceutical molecules. Includes downl
£228.00
Cambridge University Press Cyclopentaaphenanthrenes
a huge range and FREE tracked UK delivery on ALL orders.
£38.94
Cambridge University Press Cancer of the Esophagus
a huge range and FREE tracked UK delivery on ALL orders.
£37.04
Cambridge University Press Chemistry and Biology of NNitroso Compounds
a huge range and FREE tracked UK delivery on ALL orders.
£47.49
Cambridge University Press Handbook of Experimental Neurology
a huge range and FREE tracked UK delivery on ALL orders.
£60.79
Cambridge University Press Research Ethics
a huge range and FREE tracked UK delivery on ALL orders.
£46.54
Cambridge University Press Polycyclic Aromatic Hydrocarbons
a huge range and FREE tracked UK delivery on ALL orders.
£40.84
Cambridge University Press Monoclonal Antibodies
a huge range and FREE tracked UK delivery on ALL orders.
£88.34
Cambridge University Press A ClinicoGenetic Study of Psychiatric Disorder in Huntingtons Chorea
a huge range and FREE tracked UK delivery on ALL orders.
£35.14
Cambridge University Press Undertaking Sensitive Research in the Health and Social Sciences Managing Boundaries Emotions and Risks Cambridge Medicine Paperback
a huge range and FREE tracked UK delivery on ALL orders.
£57.94
Cambridge University Press Bioethics and the Future of Stem Cell Research
a huge range and FREE tracked UK delivery on ALL orders.
£62.70
Cambridge University Press Medical Statistics from A to Z
a huge range and FREE tracked UK delivery on ALL orders.
£117.00
Cambridge University Press Governance and Leadership
a huge range and FREE tracked UK delivery on ALL orders.
£17.00
Cambridge University Press Reducing Overuse
a huge range and FREE tracked UK delivery on ALL orders.
£17.00
Cambridge University Press Values and Ethics
a huge range and FREE tracked UK delivery on ALL orders.
£17.00
Cambridge University Press Statistical Process Control
a huge range and FREE tracked UK delivery on ALL orders.
£17.00
Cambridge University Press Health Economics
a huge range and FREE tracked UK delivery on ALL orders.
£47.49
Cambridge University Press Approaches to Spread ScaleUp and Sustainability
a huge range and FREE tracked UK delivery on ALL orders.
£47.49
Cambridge University Press Statistical Process Control
a huge range and FREE tracked UK delivery on ALL orders.
£47.49
Simon & Schuster Bad Blood
Book SynopsisFrom 1932 to 1972, the United States Public Health Service conducted a non-therapeutic experiment involving over 400 black male sharecroppers infected with syphilis. The Tuskegee Study had nothing to do with treatment. Its purpose was to trace the spontaneous evolution of the disease in order to learn how syphilis affected black subjects.From 1932 to 1972, the United States Public Health Service conducted a non-therapeutic experiment involving over 400 black male sharecroppers infected with syphilis. The Tuskegee Study had nothing to do with treatment. Its purpose was to trace the spontaneous evolution of the disease in order to learn how syphilis affected black subjects. The men were not told they had syphilis; they were not warned about what the disease might do to them; and, with the exception of a smattering of medication during the first few months, they were not given health care. Instead of the powerful drugs they required, they were given aspirin for their aches and pains. Health officials systematically deceived the men into believing they were patients in a government study of “bad blood”, a catch-all phrase black sharecroppers used to describe a host of illnesses. At the end of this 40 year deathwatch, more than 100 men had died from syphilis or related complications. “Bad Blood” provides compelling answers to the question of how such a tragedy could have been allowed to occur. Tracing the evolution of medical ethics and the nature of decision making in bureaucracies, Jones attempted to show that the Tuskegee Study was not, in fact, an aberration, but a logical outgrowth of race relations and medical practice in the United States. Now, in this revised edition of “Bad Blood”, Jones traces the tragic consequences of the Tuskegee Study over the last decade. A new introduction explains why the Tuskegee Study has become a symbol of black oppression and a metaphor for medical neglect, inspiring a prize-winning play, a Nova special, and a motion picture. A new concluding chapter shows how the black community''s wide-spread anger and distrust caused by the Tuskegee Study has hampered efforts by health officials to combat AIDS in the black community. “Bad Blood” was nominated for the Pulitzer Prize and was one of the “N.Y. Times” 12 best books of the year.Trade ReviewThe New York Times Book Review As an authentic, exquisitely detailed case study of the consequences of racism in American life, this book should be read by everyone who worries about the racial meanings of government policy and social practice in the United States.The Washington Post Book World This is a valuable, superbly researched, fair-minded, profoundly troubling, and clearly written book.C. Vann Woodward Author of The Strange Career of Jim Crow Bad Blood is an important book, an authentic and appalling study of how the educated deliberately deceived and betrayed the uneducated in our own times through a government agency."Benjaminl Hooks Executive Director, National Association for the Advancement of Colored People Bad Blood is a shocking and bold report of scientific cruelty and moral idiocy...The moral and ethical questions this book raises come into sharp focus and are compelling.James T. Patterson Author of The Dread Disease: Cancer & Modern American Culture By eschewing sensationalism, Jones offers a compelling narrative that enhances our understanding of race relations in the twentieth-century South, of professionalism in medicine, and of American liberalism. Bad Blood deserves to win a prize.Table of ContentsContentsPreface to the New and Expanded EditionAcknowledgmentsA Note on Spelling and Punctuation1 "A Moral Astigmatism"2 "A Notoriously Syphilis-Soaked Race"3 "Disease Germs Are the Most Democratic Creatures in the World"4 "Holding High Wasserman in the Marketplace"5 "The Dr. Ain't Taking Sticks"6 "Buying Ear Muffs for the Hottentots"7 "It Will Either Cover Us with Mud or Glory"8 "Last Chance for Special Free Treatment"9 "Bringing Them to Autopsy"10 "The Joy of My Life"11 "Even at Risk of Shortening Life"12 "Nothing Learned Will Prevent, Find, or Cure a Single Case"13 "I Ain't Never Understood the Study"14 "AIDS: Is It Genocide?"NotesA Note on SourcesIndexesAbout the Author
£21.37
Elsevier Science Publishing Co Inc Heart and Neurologic Disease
Book SynopsisTable of Contents1. Neurologic complications of pediatric congenital heart disease 2. Neurologic complications of congenital heart disease in adults 3. Neurologic complications of rheumatic fever 4. Neurologic complications of nonrheumatic valvular heart disease 5. Advances and ongoing controversies in PFO closure and cryptogenic stroke 6. Neurological complications of coronary heart disease and their management 7. Neurologic complications of heart surgery 8. Neurological complications of heart failure 9. Neurological complications of cardiomyopathies 10. Neurologic complications of myocarditis 11. Neurologic complications of infective endocarditis 12. Neurologic complications of nonbacterial thrombotic endocarditis 13. Neurologic complications of atrial fibrillation: Pharmacologic and interventional approaches to stroke prevention 14. Tachyarrhythmias and neurologic complications 15. Neurologic complications of brady-arrhythmias 16. Effects of acute neurologic disease on the heart 17. Neurologic complications of genetic channelopathies 18. Neurological complications of syncope and sudden cardiac arrest 19. Neurologic complications of cardiac arrest 20. Neurologic complications of implantable devices 21. Neurologic complications of diseases of the aorta 22. Cerebral aneurysms and cervical artery dissection: Neurological complications and genetic associations 23. Neurological complications of systemic hypertension 24. Neurologic complications of venous thromboembolism 25. Neurologic complications of cardiac disease in athletes 26. Cerebrovascular manifestations of tumors of the heart 27. Stroke in pregnancy 28. Hemodynamics in acute stroke: Cerebral and cardiac complications 29. Neurological complications of cardiovascular drugs 30. The role of biomarkers and neuroimaging in ischemic/hemorrhagic risk assessment for cardiovascular/cerebrovascular disease prevention 31. Clinical utility of echocardiography in secondary ischemic stroke prevention 32. The relationship between heart disease and cognitive impairment 33. Anxiety and psychological management of heart disease and heart surgery
£207.10
Oxford University Press Inc AMA Manual of Style A Guide for Authors and
Book SynopsisAttempting to provide editorial support to the medical and scientific publishing community, this manual presents information on ethical and legal issues, with guidelines on conflict of interest, scientific misconduct, intellectual property, and the protection of individuals' rights. It also features an international perspective on drugs.
£54.56
John Wiley & Sons Inc BenefitRisk Appraisal of Medicines A Systematic
Book SynopsisEstablishes the criteria required to assess benefit-risk in general and reviews the current practice of benefit-risk assessment by drug regulatory authorities and the pharmaceutical industry. Outlines how the new MCDA model was developed and evaluated, and discusses the implications of its implementation into the practice of drug evaluation.Table of ContentsForeword. Preface. 1 Concept and Scope of Benefit–Risk Evaluation of Medicines. 1.1 Historical backgroun. 1.2 The regulatory systems for assessing medicines. 1.3 Benefit–risk assessment: definitions. 1.4 Views and perceptions of benefits and risks of medicines. 1.5 Stages and concepts in benefit–risk assessment. 1.6 Benefit–risk assessment: the current regulatory environment. 1.7 Benefit–risk assessment in other disciplines. 1.8 Specific methods and models for benefit–risk assessment. 1.9 Discussions with stakeholders on the concepts and models for benefit–risk evaluation. 2 Criteria for a Benefit–Risk Model: a Conceptual Framework. 2.1 Introduction. 2.2 Regulatory guidelines on benefit and risk criteria. 2.3 Identification, definition and rationale of relevant benefit and risk criteria. 2.4 Verification of the list of benefit and risk criteria by means of a survey. 3 Review of the Current Benefit–Risk Assessment Models. 3.1 Background. 3.2 Evaluation of the existing benefit–risk assessment models. 3.3 Review of models in single clinical trials and for specific medicines. 3.4 Conclusion. 3.5 Newer models. 4 Defining a Systematic Approach to Decision Making. 4.1 Introduction. 4.2 Objectives and features of the ideal model for benefit–risk assessment. 4.3 The use of decision-analysis techniques for the development of the new model. 5 Development and Application of a Benefit–Risk Assessment Model Based on Multi-Criteria Decision Analysis. 5.1 Introduction. 5.2 Conceptualization of the new model. 5.3 Reasons for using decision analysis techniques in the new model. 5.4 The use of MCDA in the new model. 5.5 Development of the new model. 5.6 Applicability of the new model. 5.7 Summary. 5.8 Review of the MCDA model. 6 A Future Framework for Benefit–Risk Appraisal of Medicines. 6.1 Background. 6.2 Development of a benefit–risk framework for regulatory review of new medicines. 6.3 Prerequisites of a benefit–risk framework for the registration of a new medicine. 6.4 Current status of benefit–risk assessment among companies and agencies. 6.5 Constructing a benefit–risk framework. 6.6 Conclusion. Appendices. Appendix 1 Summary Reports of the CMR International Institute for Regulatory Science March 2004 and June 2005 Workshops on Benefit–Risk. Appendix 2 Office of Health Economics Briefing: Challenges and Opportunities for Improving Benefit–risk Assessment of Pharmaceuticals from an Economic Perspective – James Cross and Louis Garrison (August 2008). Appendix 3 Reflection Paper on Benefit–risk Assessment Methods in the Context of the Evaluation of Marketing Authorisation Applications of Medicinal Products for Human Use – Committee for Medicinal Products for Human Use (March 2008). Appendix 4 Commentaries on ‘A Quantitative Approach to Benefit–risk Assessment of Medicines’ Pharmacoepidemiology and Drug Safety, 2007, 16. Appendix 5 Forum on Benefit: Risk Decision Analysis – Summary of Discussions and Recommendations – MHRA (September 2008). References. Index.
£94.95
John Wiley & Sons Inc Designing and Conducting Research in Health and
Book SynopsisHealth education is a popular and growing undergraduate major and an occupational field that is on the rise. This easy-to-read, user-friendly book provides the information and skills needed for effective production and consumption of research.Table of ContentsTables and Figures xi Preface xiii Acknowledgments xv The Authors xvii Part 1 Understanding Important Research Concepts 1 Introduction to Research in Health and Human Performance 3 What You’ll Learn 3 Defining the Research Process 4 Research Continuum: Applied and Basic Research 10 Summary 14 Review Questions 15 Key Terms 15 2 Concepts in Research Designs 17 What You’ll Learn 17 Overview of Research Designs 18 Understanding Research Variables 20 Measuring Research Variables 24 Interpreting Research Designs 26 Summary 29 Review Questions 30 Key Terms 31 Part 2 Reviewing the Literature 3 Developing Your Research Topic and Interpreting Research Reports 35 What You’ll Learn 35 Identifying the Problem 35 Accessing Sources 44 Reading and Interpreting Research Reports 51 Summary 56 Review Questions 57 Key Terms 57 4 Writing the Review of Literature 59 What You’ll Learn 59 Developing an Outline 60 Writing Scientifically 69 Summary 79 Review Questions 80 Key Terms 80 Part 3 Understanding and Developing Research Designs 5 Quantitative Research Designs 83 What You’ll Learn 83 Descriptive Research Designs 84 Experimental Research Designs 96 Correlation Research Designs 102 Summary 104 Review Questions 105 Key Terms 105 6 Qualitative Research Designs 107 What You’ll Learn 107 Characteristics of Qualitative Research 107 Procedures in Qualitative Research 113 Types of Qualitative Research Designs 120 Summary 126 Review Questions 128 Key Terms 128 7 Mixed-Methods and Action Research Designs 129 What You’ll Learn 129 Overview of Mixed-Methods Research Designs 129 Framework for Mixed-Methods Research Designs 132 Action Research 138 Summary 142 Review Questions 144 Key Terms 144 8 Ethics in Research 145 What You’ll Learn 145 Ethics Within Research 146 Summary 159 Review Questions 160 Key Terms 160 9 Developing Your Research Proposal 161 What You’ll Learn 161 Sampling 162 Writing Your Introduction 168 Developing Your Methods 174 Summary 179 Review Questions 179 Key Terms 180 Part 4 Exploring Measurement and Analysis 10 Validity, Reliability, Objectivity 183 What You’ll Learn 183 Validity Concepts 184 Reliability Concepts 195 Objectivity Concepts 200 Summary 201 Review Questions 202 Key Terms 203 11 Introduction to Statistics and Hypothesis Testing 205 What You’ll Learn 205 Introduction to Statistics 206 Descriptive Statistics 215 Hypothesis Testing 219 Summary 224 Review Questions 225 Key Terms 225 12 Quantitative Data Analysis 227 What You’ll Learn 227 Inferential Statistics 227 Examining Relationships 230 Examining Differences 236 Examining Type I and Type II Errors 247 Summary 248 Review Questions 249 Key Terms 249 13 Qualitative Analysis: Interpreting the Data 251 What You’ll Learn 251 Recording Your Data 251 Managing Your Data 253 Writing the Report 258 Trustworthiness of the Data 265 Summary 267 Review Questions 268 Key Terms 269 14 Results and Discussion: Writing What You Found 271 What You’ll Learn 271 Results Section 272 Discussion Section 275 Writing Your Abstract 279 Summary 280 Review Questions 281 Part 5 Putting It All Together 15 Presenting Your Research 285 What You’ll Learn 285 Poster Presentations 286 Oral Presentation 295 Summary 301 Review Questions 301 Glossary 303 References 311 Index 319
£66.45
Knopf Doubleday Publishing Group Ageless
Book Synopsis
£15.30
John Wiley & Sons Inc Clinical Trials
Book SynopsisDiscusses the significance of clinical trials in the context of 21st century health care, with contributions on issues such as: The role of experiments in health care; Keeping track of trial reports; and, The nuts and bolts of doing trials. It is intended for trialists and researchers conducting efficient, high quality, and relevant studies.Table of ContentsContributors. Foreword. Preface. Acknowledgements. Comparing like with like and the development of randomisation. Why we need randomised controlled trials. Keeping track of trial reports; the experience of The Cochrane Trials Register. What have we learned from 50 years of randomised trials for people with schizophrenia. Big is still beautiful: why we still need large simple trials. Factors that limit the number, quality and progress of randomised trials. The nuts and bolts of doing trials. Building resources for randomised trials. The role of data monitoring committees. Bayesian perspectives on the ethics of trials. "Empowering" patient choice about participation in trials?. Index
£38.95
Houghton & Houghton APA The Eay Way a Quick and Simplified Guide to
Book Synopsis
£13.19
Wiley Exploratory Subgroup Analyses in Clinical
Book Synopsis
£81.00
John Wiley & Sons Population Science Methods and Approaches to
Book SynopsisGain a thorough understanding of the determinants of health among aging populations, how disparities arise in diverse communities, and what can be done Reducing health disparities among older people is critical to slowing or reversing the individual and societal impacts of aging-related conditions like Alzheimer''s and dementia. The field of population science can help us understand disparities and prevent them using community-wide strategies. Population Science Methods and Approaches to Aging and Alzheimer''s Disease and Related Dementias Research offers an overview of the population health approach, applying this framework to aging-related conditions and their determinants. By working hand-in-hand with diverse communities to address these conditions we can develop primary and secondary prevention strategies that can increase health equity for all Americans. Included topics range from population health trends and approaches to understanding community and patient en
£54.00
Johns Hopkins University Press Quality Assurance and Quality Improvement
Book SynopsisHelping human research protection program professionals create, implement, and evaluate quality assurance/quality improvement programs. Quality Assurance and Quality Improvement Handbook for Human Research is the first comprehensively designed instructional manual aimed at teaching human research protection program (HRPP) professionals how to create, implement, evaluate, and improve QA/QI programs. Geared toward institutions and individuals responsible for establishing new QA/QI programs or functions, the book offers several organizational models for consideration. It also provides practical information for improving and strengthening established programs, both big and small. Written in a conversational style, the book's step-by-step instructions make it easily accessible to those who may not be well versed in QA/QI concepts and fundamentals. Developed by the QA/QI Subcommittee of the Harvard Catalyst Regulatory Foundations, Ethics, and Law Program, which is committed to designing Table of ContentsContributors Foreword Preface AcknowledgmentsNote to Readers Chapter 1. Introduction to Quality Assurance and Quality Improvement ProgramsHila Bernstein, Jennifer A. Graf, and Jennifer HutchinsonChapter 2. Types of QA/QI Programs: A Review of Three ModelsJennifer A. Graf and Jennifer HutchinsonChapter 3. Policies and ProceduresBarbara E. Bierer and Eunice NewbertChapter 4. Investigator Site ReviewSusan Corl, Alyssa Gateman, Nareg D. Grigorian, and Sarah A. WhiteChapter 5. Evaluating IRB ComplianceJennifer A. Graf, Leslie M. Howes, Cynthia Monahan, Eunice Newbert, and Sarah A. WhiteChapter 6. Metrics and Communicating Observations of NoncomplianceLeslie M. Howes and Sarah A. WhiteChapter 7. Educational ProgrammingElizabeth Bowie and Leslie M. HowesAppendix A. Abbreviations and Acronyms Appendix B. Resources
£64.60
